The company develops novel biologics that deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes. Their protein-based platform technology, H-NOX, is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues. Omniox is focused on overcoming biochemical shortcomings in prior efforts at oxygen and nitric oxide delivery, and their biotherapeutics have the potential to provide meaningful therapeutic benefit to patients with ischemic, hypoxic, and anemic diseases in oncology, cardiovascular and stroke diseases, diabetes, trauma, surgery, and sickle cell crises.